Latest news with #OrthoPediatricsCorp
Business Upturn
01-08-2025
- Business
- Business Upturn
OrthoPediatrics Corp. Launches 3P™ Pediatric Plating Platform™ Hip System and Completes First Case
WARSAW, Ind., Aug. 01, 2025 (GLOBE NEWSWIRE) — OrthoPediatrics Corp. ('OrthoPediatrics' or the 'Company') (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced the US launch and first surgical case of the new 3P™ Pediatric Plating Platform™ Hip System, used to treat proximal femur fractures and deformities. 'The 3P Pediatric Plating Platform Hip System is an exceptional product that would not be possible without our remarkable design surgeons and development teams. By harnessing their insights and leveraging next-generation hardware, this system offers surgeons improved precision with additional fixation options. The demand being placed on implants continues to evolve, by addressing these new unmet needs while building upon this 3rd generation system will improve proximal femur care options,' said OrthoPediatrics Trauma and Deformity and OPSB division President, Joe Hauser commented. CEO, David Bailey added, 'This launch marks our inaugural Pediatric Plating Platform and underscores our commitment to expanding the platform into the most comprehensive plating portfolio in pediatric orthopedics.' Part of the Trauma & Deformity Correction suite of products, the comprehensive 3P Hip System includes a Beam Screw construct and Locking Proximal Femur Plates available in Infant, Child, and Adolescent sizes. The 3P Hip System integrates advanced implant and instrument technology to support both trauma and deformity surgeries, giving surgeons unmatched precision and a complete array of fixation options for proximal femur procedures. The first surgical case for the 3P Pediatric Plating Platform Hip System utilizing the Beam Screw construct has been completed with overwhelmingly positive feedback. Following the system launch, more than 10 cases were booked in August alone, with procedural volume expected to grow substantially in the coming months. About OrthoPediatrics Corp. Founded in 2006, OrthoPediatrics is an orthopedic company focused exclusively on advancing the field of pediatric orthopedics. As such, it has developed the most comprehensive product offering to the pediatric orthopedic market to improve the lives of children with orthopedic conditions. OrthoPediatrics currently markets over 80 products that serve three of the largest categories within the pediatric orthopedic market. This product offering spans trauma and deformity, scoliosis, and sports medicine/other procedures. OrthoPediatrics' global sales organization is focused exclusively on pediatric orthopedics and distributes its products in the United States and over 70 countries outside the United States. For more information, please visit For more information about the OrthoPediatrics Specialty Bracing portfolio, please visit Investor ContactPhilip Trip TaylorGilmartin Group [email protected] 415-937-5406
Yahoo
28-07-2025
- Business
- Yahoo
Here's Why OrthoPediatrics Corp. (KIDS) Drifted Lower in Q2
Conestoga Capital Advisors, an asset management company, released its second-quarter 2025 investor letter. A copy of the letter can be downloaded here. The second quarter began with a historically poor start but gained momentum later as tariff fears subsided and market volatility dropped precipitously. Conestoga Micro Cap Composite appreciated 15.65% net-of-fees in the second quarter but underperformed the Russell Microcap Growth Index's 20.92% return. In a highly volatile market led by high-beta and lower-quality stocks, the firm does not expect the fund to align with index performance. Please review the fund's top 5 holdings to gain insight into their key selections for 2025. In its second quarter 2025 investor letter, Conestoga Capital Advisors highlighted stocks such as OrthoPediatrics Corp. (NASDAQ:KIDS). Headquartered in Warsaw, Indiana, OrthoPediatrics Corp. (NASDAQ:KIDS) is a medical device company that provides anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions. The one-month return of OrthoPediatrics Corp. (NASDAQ:KIDS) was 5.91%, and its shares lost 28.59% of their value over the last 52 weeks. On July 25, 2025, OrthoPediatrics Corp. (NASDAQ:KIDS) stock closed at $22.75 per share, with a market capitalization of $563.495 million. Conestoga Capital Advisors stated the following regarding OrthoPediatrics Corp. (NASDAQ:KIDS) in its second quarter 2025 investor letter: "OrthoPediatrics Corp. (NASDAQ:KIDS) is the first company to focus solely on orthopedic care for the pediatric market. After being a leader in 1Q, KIDS drifted modestly lower during 2Q. KIDS reported revenue growth for 1Q ahead of street expectations. The company also raised full-year revenue guidance. However, EBITDA margins came in weaker-than-expected for 1Q due to the timing of some expenses and slightly higher SG&A. Management reiterated their EBITDA guidance for the year." A cutting edge medical device in a sterile surgical setting, being operated by a skilled surgeon. OrthoPediatrics Corp. (NASDAQ:KIDS) is not on our list of 30 Most Popular Stocks Among Hedge Funds. According to our database, 12 hedge fund portfolios held OrthoPediatrics Corp. (NASDAQ:KIDS) at the end of the first quarter compared to 8 in the previous quarter. OrthoPediatrics Corp. (NASDAQ:KIDS) reported worldwide revenue of $52.4 million in Q1 2025, up 17% compared to the first quarter of 2024. While we acknowledge the potential of OrthoPediatrics Corp. (NASDAQ:KIDS) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. In another article, we covered OrthoPediatrics Corp. (NASDAQ:KIDS) and shared Conestoga Capital Advisors' views on the company in the previous quarter. In addition, please check out our hedge fund investor letters Q2 2025 page for more investor letters from hedge funds and other leading investors. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Washington Post
07-05-2025
- Business
- Washington Post
OrthoPediatrics: Q1 Earnings Snapshot
WARSAW, Ind. — WARSAW, Ind. — OrthoPediatrics Corp. (KIDS) on Wednesday reported a loss of $10.7 million in its first quarter. The Warsaw, Indiana-based company said it had a loss of 46 cents per share. Losses, adjusted for non-recurring costs, were 39 cents per share.
Yahoo
30-04-2025
- Business
- Yahoo
Orthopediatrics Corp. (KIDS) Surged on Excellent Momentum Across All Business Segments
Conestoga Capital Advisors, an asset management company, released its first-quarter 2025 investor letter. A copy of the letter can be downloaded here. Equity markets started the year with a rally due to optimism about a strong economy and expectations of moderating inflation and lower interest rates. However, concerns over slowing earnings from major Technology companies, geopolitical tensions, and an upcoming announcement on tariffs led to a sharp decline in equities by the end of the first quarter. Investors sought safety, driving U.S. Treasury yields down. The Conestoga Small Cap Composite returned -11.35% (net) in the first quarter compared to the Russell 2000 Growth Index's -11.12% return. The Conestoga SMid Cap Composite returned -5.73% compared to the Russell 2500 Growth Index's -10.80% return. The Conestoga Micro-Cap Composite returned -8.24% vs the Russell Microcap Growth Index's return of -17.75%. Finally, the Conestoga Mid Cap Composite returned 0.96% (net), compared to the Russell Midcap Growth Index's -7.12% return. Please check the top 5 holdings of the fund for a better understanding of their best picks for 2025. In its first-quarter 2025 investor letter, Conestoga Capital Advisors highlighted stocks such as OrthoPediatrics Corp. (NASDAQ:KIDS). Headquartered in Warsaw, Indiana, OrthoPediatrics Corp. (NASDAQ:KIDS) provides anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions. OrthoPediatrics Corp.'s (NASDAQ:KIDS) one-month return was -18.09%, and its shares lost 30.57% of their value over the last 52 weeks. On April 29, 2025, OrthoPediatrics Corp. (NASDAQ:KIDS) stock closed at $21.55 per share with a market capitalization of $535.12 million. Conestoga Capital Advisors stated the following regarding OrthoPediatrics Corp. (NASDAQ:KIDS) in its Q1 2025 investor letter: OrthoPediatrics Corp. (NASDAQ:KIDS) is the first company to focus solely on orthopedic care for the pediatric market. KIDS reported better than expected fourth quarter results and reiterated guidance. The company has excellent momentum across all three business segments, trauma and deformity, bracing, and spine. KIDS also executed on their plan to drive higher profitability, with EBITDA crossing into positive territory and FCF to follow this year. A cutting edge medical device in a sterile surgical setting, being operated by a skilled surgeon. OrthoPediatrics Corp. (NASDAQ:KIDS) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 8 hedge fund portfolios held OrthoPediatrics Corp. (NASDAQ:KIDS) at the end of the fourth quarter, compared to 11 in the third quarter. OrthoPediatrics Corp. (NASDAQ:KIDS) reported revenue of $52.7 million in the fourth quarter of 2024, representing 40% growth from the comparable period. While we acknowledge the potential of OrthoPediatrics Corp. (NASDAQ:KIDS) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as NVIDIA but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock. In addition, please check out our hedge fund investor letters Q1 2025 page for more investor letters from hedge funds and other leading investors. READ NEXT: Michael Burry Is Selling These Stocks and A New Dawn Is Coming to US Stocks. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
08-03-2025
- Business
- Yahoo
Earnings Update: OrthoPediatrics Corp. (NASDAQ:KIDS) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts
Investors in OrthoPediatrics Corp. (NASDAQ:KIDS) had a good week, as its shares rose 9.2% to close at US$25.35 following the release of its annual results. Revenues were in line with expectations, at US$205m, while statutory losses ballooned to US$1.64 per share. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. We've gathered the most recent statutory forecasts to see whether the analysts have changed their earnings models, following these results. Check out our latest analysis for OrthoPediatrics Following the latest results, OrthoPediatrics' six analysts are now forecasting revenues of US$239.1m in 2025. This would be a meaningful 17% improvement in revenue compared to the last 12 months. Losses are expected to be contained, narrowing 18% from last year to US$1.28. Before this latest report, the consensus had been expecting revenues of US$240.8m and US$1.10 per share in losses. While this year's revenue estimates held steady, there was also a noticeable increase in loss per share expectations, suggesting the consensus has a bit of a mixed view on the stock. As a result, there was no major change to the consensus price target of US$39.00, with the analysts implicitly confirming that the business looks to be performing in line with expectations, despite higher forecast losses. Fixating on a single price target can be unwise though, since the consensus target is effectively the average of analyst price targets. As a result, some investors like to look at the range of estimates to see if there are any diverging opinions on the company's valuation. There are some variant perceptions on OrthoPediatrics, with the most bullish analyst valuing it at US$50.00 and the most bearish at US$26.00 per share. This is a fairly broad spread of estimates, suggesting that analysts are forecasting a wide range of possible outcomes for the business. Another way we can view these estimates is in the context of the bigger picture, such as how the forecasts stack up against past performance, and whether forecasts are more or less bullish relative to other companies in the industry. We would highlight that OrthoPediatrics' revenue growth is expected to slow, with the forecast 17% annualised growth rate until the end of 2025 being well below the historical 22% p.a. growth over the last five years. By way of comparison, the other companies in this industry with analyst coverage are forecast to grow their revenue at 7.8% annually. Even after the forecast slowdown in growth, it seems obvious that OrthoPediatrics is also expected to grow faster than the wider industry. The most important thing to take away is that the analysts increased their loss per share estimates for next year. Fortunately, they also reconfirmed their revenue numbers, suggesting that it's tracking in line with expectations. Additionally, our data suggests that revenue is expected to grow faster than the wider industry. The consensus price target held steady at US$39.00, with the latest estimates not enough to have an impact on their price targets. Following on from that line of thought, we think that the long-term prospects of the business are much more relevant than next year's earnings. At Simply Wall St, we have a full range of analyst estimates for OrthoPediatrics going out to 2027, and you can see them free on our platform here.. We don't want to rain on the parade too much, but we did also find 1 warning sign for OrthoPediatrics that you need to be mindful of. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
